Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 118 of the 123 references it cites were found in a registry or an index; 16 of the 51 sources its claims cite were checked for support.

Fenofibrate and Metabolic Syndrome

Open access
T. Kraja, Aldi, A. Province, Michael, J. Straka, Robert, M. Ordovas, Jose, B. Borecki, Ingrid, K. Arnett, Donna · 2010 · Endocrine, Metabolic & Immune Disorders - Drug Targets

Abstract

The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage patients with dyslipidemia. Typical changes in serum lipids as result a of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of -93.7 mg/dL (-39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by -17.9 mg/dL (-12.3%). The greatest reductions in serum TG are usually observed in subjects with elevated baseline TGs including those with the metabolic syndrome (MetS). Although statins remain the mainstay of therapy for most dyslipidemic patients, their combined use with FF would be expected to address residual risk resulting from less than optimal TG and HDLC levels in such patients. Clinical trials examining the cardiovascular benefits of FF alone or combined with statins have produced mixed results. These observations underscore our lack of understanding of which patients may benefit from FF therapy and which do not. Although FF's basic mechanism of action is known to involve PPAR-alpha agonist activity resulting in altered transcription of several genes, the actual genetic bases for variability in lipid response is poorly understood. Studies, such as our GOLDN study and others designed to better understand the genetic determinants of variability in the response to FF treatment and lipid levels. As a result several important genetic determinants of lipid levels have been identified. For example, in the GOLDN study SNPs from different genes were significantly associated with baseline lipid levels before treatment (APOA5- rs662799, rs3135506; APOC3- rs5128, rs2854117, rs4520); APOA4- rs5104; PPARA- rs9626730, rs135543, rs11703495; LPL- rs1801177), after treatment PPARA- rs11708495; LPL- rs1801177, and appeared to modulate overall response to FF treatment (NOS3- rs1799983). In this article, we will review the literature leading up to the contemporary use of FF as an agent to manage patients with dyslipidemia and focus on emerging understanding of the genetic variability in response to FF treatment. On the basis of the available evidence, we conclude that FF is of benefit in the treatment of dyslipidemia, especially among those with MetS. However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes.

Overview

CoChat Summary

TL;DR

This review concludes that fenofibrate benefits dyslipidemia, especially in metabolic syndrome, but which patients derive clinical outcome benefit remains unclear. It summarizes fenofibrate’s lipid effects, major trials, and GOLDN genetic associations with lipid response.

Key findings

  • In a review of 15 clinical trials using TriCor-brand fenofibrate, mean changes were triglycerides −93.7 mg/dL (−39.3%), LDL cholesterol −17.9 mg/dL (−12.3%), and HDL cholesterol +5.5 mg/dL (+12.4%).
  • In GOLDN, fenofibrate 160 mg once daily for 3–4 weeks decreased plasma triglycerides from an average 145 mg/dL to 91 mg/dL (−37.2%); subjects with metabolic syndrome had a greater triglyceride change, −108.3 mg/dL (−43.2%), than non-MetS subjects, −34.5 mg/dL (−31.4%).
  • Baseline lipid associations included SNPs in APOA5 (rs662799, rs3135506), APOC3 (rs5128, rs2854117, rs4520), APOA4 (rs5104), PPARA (rs9626730, rs135543, rs11703495), and LPL (rs1801177); after treatment, PPARA rs11708495 and LPL rs1801177 remained associated, and NOS3 rs1799983 appeared to modulate overall response.
  • Clinical outcome trials were mixed: FIELD (9,795 type 2 diabetes subjects) showed a 24% reduction in nonfatal myocardial infarction with fenofibrate versus placebo (p=0.01) but a non-significant increase in coronary heart disease mortality (p=0.22); ACCORD (5,518 type 2 diabetes patients on simvastatin) found no overall improvement in primary or secondary cardiovascular endpoints with added fenofibrate, with possible subgroup interactions by sex (P=0.01) and high-TG/low-HDL subgroup (P=0.057).

Methods

  • Narrative literature review plus original GOLDN analyses. GOLDN was a clinical familial study with a fenofibrate treatment arm and a fat-load meal arm; the maximal sampled population was 1,107 white subjects with no missing phenotypes on 10 traits, treated with fenofibrate 160 mg once daily for 3–4 weeks.
  • Candidate SNP association testing used 115 SNPs from 29 candidate genes, with multivariate factor analysis and random coefficients growth curves on repeated measures; the Bonferroni threshold was p=0.0004, and top findings were tested against LDL cholesterol, HDL cholesterol, and triglycerides.
  • The authors also reviewed 15 clinical trials using TriCor-brand fenofibrate to summarize lipid changes.

Limitations

  • The paper states that GOLDN’s 3–4 week treatment period does not allow judgment of long-term fenofibrate effects on clinical outcomes such as morbidity and mortality.
  • The paper states that its candidate-gene approach had modest contribution to lipid profile change and that there have been limited outcome trials using fenofibrate as the study drug; fenofibrate use in type 2 diabetes was “not systematically evaluated” and produced mixed results.
  • Evident from the text: as a narrative review, it does not report a systematic search or meta-analysis, and conclusions about clinical benefit rely on heterogeneous trials and subgroup findings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2174/187153010791213047

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 1 Not valid · 21 Not checked · 26 Own results and interpretations

33 more claims · 6 with their cited sources checked

Create a free account to see all 62 claims and to verify the 8 references still open.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 14
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 123 references

Research works printed but not linked: 2

  1. [58]Wang TD Chen WJ Lin JW Cheng CC Chen MF Lee YT 2003 Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles Atherosclerosis 170 315 323 14612213
  2. [72]Rubins HB Robins SJ Collins D Fye CL Anderson JW Elam MB Faas FH Linares E Schaefer EJ Schectman G Wilt TJ Wittes J for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 410 418 10438259

Cited by

See all 40

Metadata

Authors
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D.
Venue
Endocrine, Metabolic & Immune Disorders - Drug Targets
Published
2010-06-01
Volume
10
Issue
2
Pages
138-148
ISSN
1871-5303 (ISSN-L)
OpenAlex
W2114747205
Cited by
40
References
123
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 3 · 2014: 4 · 2013: 3 · 2012: 12
FWCI
0.91
Type
journal article
Language
en
Open access
Locations
  • Endocrine Metabolic & Immune Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R01HL09135701A1, R01HL091357)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
fenofibrate, metabolic syndrome, dyslipidemia, PPARα agonist, single nucleotide polymorphisms, APOA5, apolipoprotein C-III, APOA4, PPARα, lipoprotein lipase, NOS3, triglycerides, HDL cholesterol, LDL cholesterol, statin combination therapy
MeSH terms
Hypolipidemic Agents, Diabetes Mellitus, Type 2, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Fenofibrate, Triglycerides, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Metabolic Syndrome, PPAR alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fenofibrate and Metabolic Syndrome. https://app.cochat.ai/papers/10.2174/187153010791213047
The paper
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010). Fenofibrate and Metabolic Syndrome. Endocrine, Metabolic & Immune Disorders - Drug Targets. https://doi.org/10.2174/187153010791213047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.